SecBot SecBot
SECBOTREPLAY Home › Report › AXSM

AXSM · Axsome Therapeutics reported Q3 2026 net product revenue of $259.7M,…

Axsome Therapeutics, Inc. · PRESS-RELEASE filed Nov 2, 2026 at 07:00 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Nov 2, 2026 at 07:00 ET

Axsome Therapeutics reported Q3 2026 net product revenue of $259.7M, 52% YoY growth, beating the $249.2M consensus. Net loss narrowed to $12.9M ($0.25 per share) from $47.2M ($0.94 per share) a year ago, significantly better than the consensus EPS loss of $0.64. The company highlighted strong Auvelity and Sunosi prescription trends and initiated the Phase 3 SUMMIT trial for AXS-05 in smoking cessation.

  • Q3 2026 total net product revenue $259.7M, up 52% YoY from $171.0M, above consensus $249.2M.
  • Net loss $12.9M ($0.25 per share) vs $47.2M ($0.94 per share) YoY, beating consensus EPS loss of $0.64.
  • Auvelity net product sales $207.6M, up 53% YoY; total prescriptions ~302,000, up 40% YoY.
  • Sunosi net product revenue $48.2M, up 47% YoY; prescriptions up 15% YoY.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access